Related Experiment Video
Updated: Aug 11, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
The long-term behavior and predictors of left ventricular hypertrophy in hemodialysis patients
Sim Kutlay1, Irem Dincer, Sule Sengül
1Department of Nephrology, Ankara University School of Medicine, Ankara, Turkey.
Insights
Left ventricular hypertrophy (LVH) is not inevitable in hemodialysis (HD) patients. Aggressive treatment targeting predictors like C-reactive protein and blood pressure may regress left ventricular mass index (LVMI) and improve outcomes.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Left ventricular hypertrophy (LVH) is a common complication in patients undergoing hemodialysis (HD).
- Understanding the long-term behavior of LVH and its predictors is crucial for managing cardiovascular risk in this population.
Purpose of the Study:
- To evaluate the long-term behavior of LVH in HD patients.
- To identify predictors of changes in left ventricular mass index (LVMI).
Main Methods:
- 108 HD patients underwent annual echocardiography and 24-hour ambulatory blood pressure monitoring.
- Left ventricular mass index (LVMI) was assessed, with LVH defined by specific thresholds for men and women.
- Median follow-up was 50 months, with a median of 4 echocardiographic examinations per patient.
Main Results:
- 75.9% of patients had LVH at baseline; LVH status changed in 40.7% during follow-up.
- LVMI decreased by 8.0 g/m2 on average. Key predictors of LVMI change included C-reactive protein, baseline hemoglobin, and postdialysis systolic blood pressure.
- 24-hour systolic blood pressure predicted baseline LVMI and LVH, while nighttime systolic blood pressure and C-reactive protein predicted final LVMI.
Conclusions:
- Progressive LVH is not inevitable in hemodialysis patients.
- Targeting identified predictors, such as C-reactive protein and blood pressure, may lead to regression of LVMI.
- Interventions aimed at these predictors could potentially improve patient outcomes.
Background:
The long-term behavior of left ventricular hypertrophy (LVH) was evaluated and potential predictors of change in left ventricular mass index (LVMI) in hemodialysis (HD) patients were determined.
Methods:
One hundred eight patients on regular HD treatment were included. In addition to hematologic and biochemical evaluations, annual echocardiography and 24-hour ambulatory blood pressure monitoring were performed in all patients. During the median follow-up of 50 months (range, 12 to 63 months), a median of 4 echocardiographic examinations were performed in each patient. The presence of LVH was defined on the basis of an LVMI greater than 131 g/m2 for men and greater than 100 g/m2 for women.
Results:
Eighty-two patients (75.9%) had LVH at baseline. LVH status was stable in 64 patients, whereas it changed on at least 1 occasion in the remaining patients (40.7%). LVH disappeared during the first year in 8 patients and beyond the first year of dialysis therapy in an additional 9 patients. An 8.0 +/- 39.6-g/m2 decrease in LVMI was detected between the first and final evaluations. Independent predictors of change in LVMI were C-reactive protein level (P < 0.001), baseline hemoglobin level (P = 0.025), and baseline postdialysis systolic blood pressure (P = 0.003). Twenty-four-hour systolic blood pressure was the only independent predictor of both LVMI (P < 0.001) and LVH (P = 0.001) at baseline. Nighttime systolic blood pressure and C-reactive protein level were found to be independent predictors of final LVMI (P < 0.001 for both). Independent predictors of LVH at the end of the study were 24-hour systolic blood pressure (P = 0.022) and C-reactive protein level (P = 0.003), whereas hemoglobin level had marginal significance (P = 0.051).
Conclusion:
Progressive LVH is not inevitable in HD patients. Aggressive treatment against the predictors may result in regression of LVMI and may improve patient outcome.
Related Concept Videos
Heart Failure II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure VI: Adjunct Therapies
Pathophysiology of Heart Failure
Hemodialysis III: Nursing Management
Hemodialysis I: Introduction
